Enterprise ODM Finger Print Supplier & Contract Analysis

Conventional titration or single-analyte HPLC only confirms the presence of one chemical molecule. This allows sub-standard materials to pass testing if synthetic or isolated chemicals are artificially spiked into low-grade botanicals. Chromatographic fingerprinting (HPTLC, HPLC-DAD, GC-MS) captures the holistic multi-component profile of the plant. By examining characteristic peak distributions, retention times, and relative area ratios, our fingerprint service verifies species authenticity, botanical origin, and overall pharmacological integrity, completely eliminating adulteration risks.

Our central analytical laboratories in Changsha feature Agilent 1260/1290 Infinity II HPLCs, Waters ACQUITY UPLC systems coupled with photodiode array (PDA/DAD) detectors, CAMAG HPTLC automation suites, and Shimadzu GC-MS platforms. For mathematical similarity calculations, we utilize the authoritative State Pharmacopoeia Commission's Similarity Evaluation System for Chromatographic Fingerprints (SESCF), generating correlative coefficients and vector angle metrics (cosine values) for all commercial production batches.

Yes. MedGence acts as a comprehensive CRO and CDMO partner. We develop validated analytical methodologies adhering strictly to ICH Q2(R1) guidelines, execute GLP-like acute and chronic animal toxicity evaluations, perform in vitro cellular mechanism studies, and organize Phase I to Phase IV GCP clinical trials. Our documentation packages are designed to satisfy regulatory authorities including China NMPA, US FDA, and EMA.

Botanical potency naturally shifts based on harvest timing, elevation, and regional climate. MedGence maintains an expansive geo-potency evaluation database tracking active compound yields across multiple harvest seasons and origins. By applying dynamic extraction adjustments and proprietary batch-blending algorithms before commercial extraction, our smart production plant delivers finished bulk extracts that fall consistently within strict fingerprint and assay boundaries.

All ODM/OEM contract research, method creation, and CDMO production services are executed under binding Non-Disclosure Agreements (NDAs). MedGence operates strictly as an entrusted B2B service organization; clients maintain full ownership of proprietary formulas, patented extraction protocols, and analytical deliverables. Production line data and analytical files are segmented and stored in secure, encrypted servers.

Our CDMO infrastructure supports both bulk active ingredients and packaged consumer formats. Bulk forms include standardized liquid concentrates, spray-dried extract powders, pastes, and purified essential oils. Finished product forms encompass high-clarity oral liquids, hard two-piece capsules, enteric-coated softgels, compressed tablets, and fast-dissolving effervescent granules.